Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $1.7 million.

  • Aytu Biopharma's Net Cash Flow rose 1545.10% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 8595.83%. This contributed to the annual value of $10.9 million for FY2025, which is 467.44% up from last year.
  • Aytu Biopharma's Net Cash Flow amounted to $1.7 million in Q3 2025, which was down 86.87% from $12.8 million recorded in Q2 2025.
  • Aytu Biopharma's Net Cash Flow's 5-year high stood at $13.0 million during Q1 2021, with a 5-year trough of -$9.3 million in Q3 2021.
  • In the last 3 years, Aytu Biopharma's Net Cash Flow had a median value of $231,000 in 2024 and averaged $1.2 million.
  • Over the last 5 years, Aytu Biopharma's Net Cash Flow had its largest YoY gain of 5,094.72% in 2025, and its largest YoY loss of 1,063.20% in 2025.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Net Cash Flow stood at -$5.3 million in 2021, then climbed by 18.05% to -$4.3 million in 2022, then spiked by 89.94% to -$435,000 in 2023, then surged by 166.67% to $290,000 in 2024, then skyrocketed by 1,545.10% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $12.8 million for Q2 2025, and -$2.2 million during Q1 2025.